Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy

By Shayne Michelle   Crawford Jeffrey   Dale David   Culakova Eva   Lyman Gary  

Breast Cancer Research and Treatment, Vol. 100, Iss. 3, 2006-12 ,pp. : 255-262

Springer Publishing Company

Access to resources Recommend Favorite

Health-Related Quality of Life in Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer Patients Undergoing AC Versus CMF Chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23

By Land Stephanie   Kopec Jacek   Yothers Greg   Anderson Stewart   Day Richard   Tang Gong   Ganz Patricia   Fisher Bernard   Wolmark Norman  

Breast Cancer Research and Treatment, Vol. 86, Iss. 2, 2004-07 ,pp. : 153-164

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant chemotherapy for breast cancer in patients with schizophrenia

By            

Oncology Letters, Vol. 3, Iss. 4, 2012-01 ,pp. : 845-850

Spandidos Publications

Access to resources Recommend Favorite

Racial Disparity in the Dose and Dose Intensity of Breast Cancer Adjuvant Chemotherapy

By Griggs J.J.  

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-09 ,pp. : 21-31

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer

By Fountzilas George   Pectasides Dimitrios   Christodoulou Christos   Timotheadou Eleni   Economopoulos Theofanis   Papakostas Pavlos   Papadimitriou Christos   Gogas Helen   Efstratiou Ioannis   Skarlos Dimosthenis  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 479-488

Humana Press, Inc

Access to resources Recommend Favorite